SEC Filing Analysis: RELMADA THERAPEUTICS, INC. (RLMD)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: The Chief Operating Officer made a $198,000 open-market purchase, acquiring a meaningful 0.27% of the company's total outstanding shares.
• Market Impact: This filing is a bullish signal, reflecting strong internal confidence from a C-suite executive in a small-cap company.

Company Information

Field	Value
Company	RELMADA THERAPEUTICS, INC.
Ticker Symbol	RLMD
CIK	0001553643
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	Kelly Paul Edward
CIK	0001658544
Title/Position	Chief Operating Officer
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-05
Transaction Code	P (Open market purchase)
Security Type	Common Stock
Shares Involved	90,000
Price Per Share	$2.20
Total Value	$198,000
Shares Owned After	502,295
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$198,000
% of Market Cap	0.28%
Shares Transacted	90,000
% of Shares Outstanding	0.27%
Post-Transaction Ownership	502,295 shares (1.51% of outstanding)
Materiality Assessment	Medium

Impact Evaluation

• Market Cap Context: For a small-cap company valued at $70 million, a $198,000 purchase is a moderately significant investment from an executive, demonstrating substantial personal conviction.
• Ownership Concentration: The COO's ownership has increased to 1.51% of the company. This purchase increased the insider's holdings by approximately 22%, a significant boost to their personal stake.
• Transaction Significance: The transaction is notable not for its absolute dollar value, but because it represents 0.27% of the company's total shares outstanding. A purchase of this relative size by a top executive is a strong signal of internal confidence.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: While a C-suite insider buy is a positive signal, the transaction's value is less than 0.3% of the market cap, which may not be sufficient to drive a significant, sustained price move on its own.

Volume & Sentiment

• Expected Volume Impact: A potential short-term increase in trading volume as the market digests the signal from a key insider.
• Sentiment Indicator: Bullish

Investment Insights

Positive Market Indicators

• A C-suite executive (COO) used personal funds for an open-market purchase, not a grant or option exercise.
• The transaction significantly increases the insider's personal holdings by ~22%.
• The purchase represents a non-trivial percentage (0.27%) of the company's total shares outstanding.

Risk Factors

• The company is a small-cap pharmaceutical firm, which carries inherent market volatility and clinical trial risks.
• The absolute transaction value is not transformative at the company level.

Key Takeaways

1. The COO of Relmada Therapeutics has demonstrated strong conviction by purchasing $198,000 worth of company stock on the open market.
2. The transaction is moderately significant, representing 0.27% of total shares outstanding for the $70M market cap company.
3. This buy increases the COO's total ownership to over 1.5% of the company, strengthening the alignment of executive and shareholder interests.

Additional Context

Transaction Notes

• Timing: The transaction was an open-market purchase (Code 'P'), indicating a direct investment of personal capital rather than an equity award.